Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North…
| Price | $67.13 |
|---|---|
| Market cap | $5.97B |
| Sector | Healthcare |
| Industry | Medical - Pharmaceuticals |
| Exchange | NASDAQ |
| 52-week range | 21.15-93.61 |
| Beta | 0.54 |
Explore LQDA's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.